Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Upper-Extremity Deep Vein Thrombosis in Cancer: Beyond a Catheter-Related Complication.

JACC. CardioOncology·2026
Same author

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

Cancer·2026
Same author

A blood-based immune-suppressive index stratifies immunotherapy outcomes in advanced NSCLC.

Frontiers in immunology·2026
Same author

Exploring genomic analysis and methylome profiling in longitudinal series of p.G12C KRAS mutated NSCLC patients treated with sotorasib.

The journal of liquid biopsy·2026
Same author

Unraveling lung cancer dynamics: a new metabolic signature improving the prediction of recurrence in resected lung adenocarcinoma.

Journal of translational medicine·2026
Same author

NeoProspect HER2-low: Response and Prognosis After Neoadjuvant Treatment in Patients with HER2-low Breast Cancer.

Cureus·2026

Related Experiment Video

Updated: Jun 4, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The

Francesco Passiglia1, Angela Listì1, Paolo Bironzo1

  • 1Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano, Turin, Italy.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|December 18, 2024
PubMed
Summary

The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA) successfully provided free molecular profiling for non-small cell lung cancer (NSCLC) patients. This initiative improved access to targeted therapies and clinical trials, enhancing patient outcomes.

Keywords:
AdvocacyBiomarker testingClinical trialsLung cancerPrecision medicineTargeted therapy

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing
11:02

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 18, 2013

19.4K

Related Experiment Videos

Last Updated: Jun 4, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing
11:02

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 18, 2013

19.4K

Area of Science:

  • Oncology
  • Genomics
  • Clinical Pathology

Background:

  • The Women Against Lung Cancer in Europe (WALCE) advocacy group initiated the European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).
  • EPROPA offered a free molecular profiling platform for non-small cell lung cancer (NSCLC) to identify targetable drivers and improve clinical trial access in Europe.

Purpose of the Study:

  • To assess the feasibility and utility of a routine molecular profiling program for advanced NSCLC in a real-world European setting.
  • To increase the detection of targetable oncogenic alterations and facilitate patient enrollment in clinical trials.

Main Methods:

  • 20 European centers across five countries participated from January 2021 to December 2023, registering 555 advanced NSCLC patients.
  • Comprehensive genomic profiling using next-generation sequencing was performed on collected tissue samples.
  • Molecular reports were reviewed in a molecular tumor board to determine clinical trial eligibility.

Main Results:

  • The average turnaround time for molecular analysis was eight days, with 94% of samples being suitable.
  • 570 molecular alterations were identified in 525 analyzed samples, including 264 targetable oncogenic alterations and 113 cases with co-occurring mutations.
  • 30 patients were enrolled in clinical trials, and survival outcomes improved for those receiving matched targeted therapy.

Conclusions:

  • The EPROPA program demonstrated feasibility and utility in real-world practice for NSCLC molecular characterization.
  • Implementation of next-generation sequencing-based profiling can reduce disparities in access to tests, drugs, and clinical trials across Europe.